BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CXA-201: Phase III started

Cubist began a double-blind, international Phase III trial to compare 1,500 mg IV CXA-201 given every 8 hours for 7 days vs. IV levofloxacin in about 775 patients. The company expects to...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >